DurgicalDurgical
EN
Open the app

Nalbuphine !

An injectable κ-agonist, μ-antagonist opioid. It has a respiratory ceiling and can partly reverse μ-agonist respiratory depression, but precipitates withdrawal.

Updated 2026-11-01

The figure shows naloxone, to which nalbuphine is chemically related, in the inactive μ receptor; nalbuphine occupies the same site.

Target in 3D: κ (agonist) and μ (antagonist) opioid receptors. PDB structure 9BJK (RCSB PDB, public domain). View the structure at RCSB PDB

Mechanism of action

Nalbuphine, chemically related to naloxone and oxymorphone, is a κ-receptor agonist and a μ-receptor antagonist. κ activation produces pain relief; μ blockade explains its ceiling on respiratory depression and why, given after a μ agonist, it can partly reverse the respiratory depression that agonist causes. Naloxone reverses its own effects.

  1. Activates the κ receptor: pain relief
  2. Blocks the μ receptor
  3. A ceiling on respiratory depression
  4. After a μ agonist: partly reverses depression or precipitates withdrawal

Pharmacokinetics

Absorption
Given intravenously, intramuscularly or subcutaneously.
Metabolism
Liver.
Half-life
About 5 hours; pain relief lasts 3 to 6 hours.

Indications

  • Pain needing an opioid
  • Obstetric analgesia during labour and delivery
  • Supplement to balanced anaesthesia and pre- and postoperative analgesia

Adverse effects

Common

  • Sedation
  • Sweating
  • Nausea and vomiting
  • Itching, flushing and orthostatic hypotension from histamine release

Contraindications

  • Significant respiratory depression
  • Acute or severe bronchial asthma without monitoring or resuscitation equipment
  • Known or suspected gastrointestinal obstruction, including paralytic ileus
  • Hypersensitivity to the drug

Key interactions

Benzodiazepines, alcohol and other central nervous system depressants
Add up to profound sedation, respiratory depression, coma and death.
Full μ agonists (morphine, fentanyl) in use or dependence
Can weaken their pain relief and precipitate withdrawal in dependent patients.
Naloxone
Reverses the respiratory depression caused by nalbuphine.

What is monitored

  • Respiratory rate and sedation
  • Heart rate and blood pressure
  • In labour: fetal heart rate and the newborn's breathing

Administration and safety

  • It can be given intravenously, intramuscularly or subcutaneously.
  • Before giving it, ask about opioid use so as not to precipitate withdrawal.
  • Controlled medicine: the order is verified, every dose recorded and leftovers kept secure.

Nursing care

  • Before each dose: respiratory rate, oxygen saturation and sedation level; hold the dose and report excessive sedation or slow breathing.
  • Keep naloxone at hand and teach the family to recognise an overdose.
  • Watch the heart rate, above all in the surgical setting.
  • In obstetric analgesia, watch the fetus and the newborn.

Pregnancy and breastfeeding

It is used in labour; it can affect the fetal heart rate and depress the newborn's breathing, so both are watched.

Test yourself

Think of the answer, then tap the question to see it.

What does nalbuphine do at each opioid receptor?

It is a κ-receptor agonist and a μ-receptor antagonist.

What can happen if nalbuphine is given to a patient who received morphine?

It can partly reverse morphine's respiratory depression and, if the patient is dependent, precipitate withdrawal.

Does naloxone reverse nalbuphine's respiratory depression?

Yes; although it is an agonist-antagonist, its respiratory depressant effects are reversed by naloxone.

Add to my cards (3)

← Back to the class: Opioids and antagonists

Educational content on how drugs work; not a prescribing guide and no substitute for a health professional's advice. No doses are given.

Sources: Nalbuphine Injection: MedlinePlus Drug Information (MedlinePlus (U.S. National Library of Medicine), 2026); NALBUPHINE HYDROCHLORIDE injection, solution (DailyMed (U.S. National Library of Medicine), 2026); Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed., ch. 23 (McGraw Hill, 2023); ATCDDD - ATC/DDD Index (WHO Collaborating Centre for Drug Statistics Methodology, 2026).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.